Hemab Therapeutics Holdings, Inc. (COAG)
$44.84-$4.65 (-9.40%) Today
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 67,669 | $1.69M |
9 Form 4 filings on record, the earliest from May 4, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 6,146 | $24.89 | $153K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 61,523 | $24.98 | $1.54M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 3,802 | $24.97 | $95K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 996 | $24.94 | $25K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 6,387 | $24.90 | $159K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 7,921 | $24.34 | $193K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 1,985 | $24.95 | $50K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 1,483 | $24.98 | $37K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 14,149 | $24.47 | $346K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 25,720 | $25.00 | $643K | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 3,607,846 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 1,009,052 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 221,188 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 2,541,250 | $18.00 | $45.74M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 133,750 | $18.00 | $2.41M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 87,143 | $24.59 | $2.14M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 10,268 | $25.00 | $257K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 14,611 | $23.77 | $347K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 53,407 | $24.83 | $1.33M | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series A Preferred Stock | 64,680 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series A Preferred Stock | 27,720 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series B Preferred Stock | 42,341 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series B Preferred Stock | 18,146 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series C Preferred Stock | 56,972 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Series C Preferred Stock | 10,054 | - | - | |
| Novo Holdings A/S | Other | Common Stock | 4,180,550 | - | - | |
| Novo Holdings A/S | Other | Series Seed Preferred Stock | 23,343 | $0.00 | - | |
| Novo Holdings A/S | Other | Series A Preferred Stock | 71,866 | $0.00 | - | |
| Novo Holdings A/S | Other | Series B Preferred Stock | 62,121 | $0.00 | - | |
| Novo Holdings A/S | Other | Series C Preferred Stock | 32,695 | $0.00 | - | |
| John Maraganore | Other | Common Stock | 17,974 | - | - | |
| John Maraganore | Other | Common Stock | 17,974 | - | - | |
| John Maraganore | Grant or award | Warrants (Right to Buy) | 107,338 | $0.00 | - | |
| John Maraganore | Other | Series B Preferred Stock | 817 | $0.00 | - | |
| John Maraganore | Other | Series C Preferred Stock | 817 | $0.00 | - | |
 Catherine Madigan - Officer | Grant or award | Warrants (Right to Buy) | 145,134 | $0.00 | - | |
| Catherine Madigan - Officer | Grant or award | Stock Option (Right to Buy) | 49,016 | $0.00 | - | |
| Mads Nikolaj Behrndt-Eriksen - Officer | Grant or award | Stock Option (Right to Buy) | 49,016 | $0.00 | - | |
| Mads Nikolaj Behrndt-Eriksen - Officer | Grant or award | Warrants (Right to Buy) | 195,206 | $0.00 | - |
Hemab Therapeutics Holdings, Inc. (COAG) had 1 insider filing in the last 90 days, with the most recent on 2026-06-17. The full record for COAG runs to 9 Form 4 filings, the earliest from 2026-05-04. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
2 insider purchases of COAG were filed in the last 90 days, totaling $1.69M.
No insider sales of COAG were filed in the last 90 days.
This page tracks COAG Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add COAG to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
